Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2).
The prostaglandin endoperoxide H synthase-1 (PGHS-1) and prostaglandin endoperoxide H synthase-2 (PGHS-2) are the targets of non-steroidal anti-inflammatory drugs (NSAIDs). The high degree of selectivity for inhibition of PGHS-2 shown by certain compounds appears to stem from two mechanisms (time-dependent, time-independent inhibition) by which they interact with each isoform. Molecular models of the complexes between indomethacin, fenamates, 2-phenylpropionic acids and the selective cyclooxygenase-2 (COX-2) inhibitors, with the cyclooxygenase active site of human PGHS-2 have been built by combining homology modelling, conformational searching and automated docking techniques. The stability of the resulting complexes has been assessed by molecular dynamics simulations combined with extended linear response calculations. The results allow us to identify regions of biological significance consistent with both X-ray crystallographic and kinetic results. The selective PGHS-2 inhibitors exploit the extra space of a side-pocket in the active site of PGHS-2 that is not found in PGHS-1. The results obtained point out a marked relationship between the experimental affinity and the electrostatic interaction energy alone for a series of NSAIDs. Analysis of the structural and the energetic data provides evidence supporting that network of hydrogen bonds between Tyr355, Glu524, Arg120 and Arg513 might be involved in mediating the binding of the time-dependent inhibitors of PGHS-2.
Pouplana
R
R
Departament de Fisicoquímica, Facultat de Farmàcia, Universitat de Barcelona, Spain. ramon@farmacia.far.ub.es
Lozano
J J
JJ
Ruiz
J
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry*; D003196:Computer Graphics; D003198:Computer Simulation; D018360:Crystallography, X-Ray; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000737:chemistry*; D004008:Diclofenac / Q000737:chemistry; D004735:Energy Transfer; D005480:Flurbiprofen / Q000737:chemistry; D006801:Humans; D007213:Indomethacin / Q000737:chemistry; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000737:chemistry; D007660:Ketoprofen / Q000737:chemistry; D008469:Meclofenamic Acid / Q000737:chemistry; D008528:Mefenamic Acid / Q000737:chemistry; D008565:Membrane Proteins; D008958:Models, Molecular; D009288:Naproxen / Q000737:chemistry; D009578:Nitrobenzenes / Q000737:chemistry; D011451:Prostaglandin-Endoperoxide Synthases / Q000737:chemistry; D011720:Pyrazoles / Q000737:chemistry; D013449:Sulfonamides / Q000737:chemistry
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D009578:Nitrobenzenes; D011720:Pyrazoles; D013449:Sulfonamides; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D004008:Diclofenac; C090859:1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole; D008528:Mefenamic Acid; D008469:Meclofenamic Acid; D009288:Naproxen; D005480:Flurbiprofen; D007660:Ketoprofen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D007213:Indomethacin